Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 40 Erie St Ste 130 CAMBRIDGE MA 02139-4254 |
Tel: | 1-857-7061612 |
Website: | https://www.intelliatx.com |
IR: | See website |
Key People | ||
John M. Leonard President, Chief Executive Officer, Director | Glenn G. Goddard Chief Financial Officer, Executive Vice President, Treasurer | Eliana Clark Executive Vice President, Chief Technology Officer |
Laura Sepp-Lorenzino Executive Vice President, Chief Scientific Officer | James Basta Executive Vice President, General Counsel, Corporate Secretary | Derek Hicks Executive Vice President, chief business officer |
David Lebwohl Executive Vice President, Chief Medical Officer | Michael P. Dube Chief Accounting Officer, Vice President |
Business Overview |
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases. |
Financial Overview |
For the fiscal year ended 31 December 2023, Intellia Therapeutics Inc revenues decreased 30% to $36.3M. Net loss increased 1% to $481.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects genome editing-based therapies segment loss increase of 12% to $515.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$6.16 to -$5.42. |
Employees: | 526 as of Feb 16, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,186M as of Dec 31, 2023 |
Annual revenue (TTM): | $36.28M as of Dec 31, 2023 |
EBITDA (TTM): | -$506.32M as of Dec 31, 2023 |
Net annual income (TTM): | -$481.19M as of Dec 31, 2023 |
Free cash flow (TTM): | -$408.07M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 96,106,405 as of Feb 16, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |